everolimus + corticosteroids

This drug refers to the **combination of everolimus**, a selective inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), and **corticosteroids**, a class of steroid hormones (most commonly prednisone or similar agents). Everolimus inhibits the mTOR pathway, thereby blocking downstream signals involved in protein synthesis, cell proliferation, angiogenesis, and survival, and is used primarily in oncology and transplant immunosuppression. Corticosteroids are broad immunosuppressive and anti-inflammatory agents acting via the glucocorticoid receptor, resulting in decreased cytokine production and multiple effects on immune modulation. This combination has been explored primarily to mitigate adverse events related to everolimus (such as noninfectious pneumonitis and stomatitis) and is under investigation for enhanced safety or efficacy in certain cancer or transplant settings[1][2][3][6].

Other names

everolimus plus corticosteroidseverolimus + prednisone